SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Marksans Pharma informs about press release

18 Apr 2024 Evaluate
Marksans Pharma has informed that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the USFDA at the manufacturing facility of the Company located in Vema, Goa, India from 9th April 2024 to 17th April 2024. On conclusion of the inspection, the Company has received 5 inspectional observations in Form 483. There is no data integrity observation. The Company will work closely with the USFDA and is committed to address these observations comprehensively within the stipulated time.

The above information is a part of company’s filings submitted to BSE.

Marksans Pharma Share Price

190.80 -2.25 (-1.17%)
24-Apr-2026 11:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1626.45
Dr. Reddys Lab 1316.60
Cipla 1286.00
Zydus Lifesciences 930.95
Lupin 2296.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×